Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.86 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.86 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.86 |
| ▸ | IKZF1 | Q13422 | 3/20 | 0.86 |
| ▸ | TNF | P01375 | 3/20 | 0.86 |
| ▸ | IL1B | P01584 | 2/20 | 0.86 |
| ▸ | BRD4 | O60885 | 1/20 | 0.86 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | MAP1LC3B | Q9GZQ8 | 6/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19612057 | 1.00 | CRBN (0.86) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL18270884 | 1.00 | CRBN (0.86) | CRBNIKZF3DDB1IKZF1TNF | |
| Lenalidomide SCHEMBL29377496 | 0.93 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1TNF | |
| Lenalidomide SCHEMBL10192655 | 0.93 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1TNF | |
| Lenalidomide SCHEMBL30876939 | 0.93 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1TNF | |
| Lenalidomide SCHEMBL10192650 | 0.93 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1TNF | |
| Lenalidomide SCHEMBL29414335 | 0.93 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1TNF | |
| Lenalidomide SCHEMBL18825 | 0.93 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1TNF | |
| Lenalidomide SCHEMBL10192663 | 0.93 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1TNF | |
| Lenalidomide SCHEMBL868339 | 0.93 | CRBN (1.00) | CRBNIKZF3DDB1IKZF1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | SALARIUS PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210340125-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | SALARIUS PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773080-B2 | Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same | HPGDS, HPGD, AQP3 | CRBN 1079/4885IKZF3 318/4885DDB1 690/4885 |
| US-20210340125-A1 | DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME | HPGDS, HPGD, AQP3 | CRBN 1079/4885IKZF3 318/4885DDB1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.